LL-37 is the human cathelicidin antimicrobial peptide. It is not in the evidence datasets this site draws on, and this page cites no primary sources for it, so the page makes no claim about what LL-37 does in animals or people. Browse the full peptide library for compounds with sourced evidence.
Longevity · Compound
LL-37
The human cathelicidin antimicrobial peptide, not yet in the evidence datasets this site draws on.
LL-37 is not yet in the evidence datasets this site draws on, so this page makes no claim about what it does.
What is LL-37
How it works
This page cites no primary source for how LL-37 works, so no mechanism is described here.
Benefits studied
LL-37 is not yet in the evidence datasets this site draws on, so this page makes no claim about what it does. Anything published about it elsewhere should be read with its evidence level in mind: most peptides in this category have animal or cell data only.
Side effects reported
No controlled human data on adverse events for LL-37 is in the datasets this site draws on, so its safety in people is unknown rather than established. Effects commonly described for it are listed below; how often they occur has not been measured in a controlled trial.
- Injection site irritation
- Redness at the injection site
- Inflammatory reaction
Regulatory status
The regulatory dataset this site draws on has no row for LL-37.
Who should not use LL-37
FAQ
What evidence exists for LL-37?
LL-37 is not in the evidence datasets this site draws on, and this page cites no primary sources for it. The page therefore states no evidence level and no finding for LL-37.
Has LL-37 been shown to treat Lyme disease?
No human trial of LL-37 in Lyme disease is in the datasets or sources this site draws on, so this page makes no claim that it treats Lyme disease.
What is known about the long-term safety of LL-37?
Its long-term safety in people is unknown. No controlled human data on adverse events for LL-37 is in the datasets this site draws on, so its safety is unknown rather than established.
Where to get LL-37 in the Philippines
Primara Labs, our partner and supplier, lists their current vials on the catalogue. Prices and stock change, so check there for what is available now. View the Primara Labs catalogue
The supply index covers what to ask a seller before paying, and why quoted prices vary so widely.
Risk · Disclosure · Editorial Status
This page is editorial information for adults researching peptide therapy. It is not medical advice, not a prescription, and not an endorsement of any specific product, supplier, or protocol. Side effects can be serious and individual response varies. Talk to a licensed physician (ideally one with peptide-specific clinical experience) before starting any compound, adjusting a dose, or discontinuing therapy.
In the Philippines, GLP-1 medications are prescription-only under FDA Philippines regulation. Research-grade peptides occupy a regulatory gray area: import for personal research use is generally tolerated, but the Bureau of Customs reserves the right to inspect and detain shipments. Do not import for resale.
- Editorial Status
- Non-clinical
- Affiliation
- Not a clinic · Not a pharmacy
- Last Updated
- September 24, 2026